Publications in collaboration with researchers from Hospital General Universitario de Elche (65)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (Trials, (2021), 22, 1, (851), 10.1186/s13063-021-05777-6)

    Trials

  2. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

    EBioMedicine, Vol. 95, pp. 104773

  3. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2022

  1. Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMI-CVID registry

    Frontiers in Immunology, Vol. 13

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

    Frontiers in Immunology, Vol. 13

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 8, pp. 372-382

  4. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

  5. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

2020

  1. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network

    Travel Medicine and Infectious Disease, Vol. 29, pp. 51-57

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  3. Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients

    PLoS ONE, Vol. 14, Núm. 8

  4. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

  5. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38